Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Nektar Therapeutics (NKTR) since 2015 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Nektar Therapeutics. Table 2 shows the detailed insider transactions. This company's CIK number is 906709.
Total stock buying since 2015: $1,380,381.
Total stock sales since 2015: $232,957,638.
Total stock option exercises since 2015: $64,061,600.
Insider Buying | Insider Sales | Option Exercises | ||||
---|---|---|---|---|---|---|
Year | Shares | Value | Shares | Value | Shares | Value |
2025 | 0 | $0 | 93,989 | $213,902 | 0 | $0 |
2024 | 0 | $0 | 383,431 | $446,447 | 0 | $0 |
2023 | 0 | $0 | 198,698 | $243,015 | 0 | $0 |
2022 | 0 | $0 | 287,002 | $1,338,751 | 0 | $0 |
2021 | 0 | $0 | 1,014,438 | $19,214,807 | 857,844 | $8,374,525 |
2020 | 0 | $0 | 272,486 | $5,487,307 | 147,500 | $1,286,775 |
2019 | 15,000 | $259,200 | 759,188 | $22,794,714 | 719,119 | $6,026,072 |
2018 | 5,000 | $290,431 | 1,255,625 | $101,982,187 | 1,060,964 | $11,098,812 |
2017 | 35,000 | $628,250 | 2,330,497 | $52,704,314 | 2,405,467 | $22,656,144 |
2016 | 15,000 | $202,500 | 687,748 | $10,451,012 | 786,583 | $3,364,205 |
2015 | 0 | $0 | 1,435,718 | $18,081,182 | 1,563,334 | $11,255,067 |
Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
---|---|---|---|---|---|---|
year-month | Shares | Value | Shares | Value | Shares | Value |
2025-09 | 0 | $0 | 1,985 | $59,838 | 0 | $0 |
2025-08 | 0 | $0 | 2,974 | $79,077 | 0 | $0 |
2025-05 | 0 | $0 | 43,916 | $29,423 | 0 | $0 |
2025-02 | 0 | $0 | 45,114 | $45,564 | 0 | $0 |
2024-12 | 0 | $0 | 183,145 | $179,696 | 0 | $0 |
2024-11 | 0 | $0 | 30,470 | $30,773 | 0 | $0 |
2024-08 | 0 | $0 | 27,398 | $35,068 | 0 | $0 |
2024-06 | 0 | $0 | 19,500 | $23,400 | 0 | $0 |
2024-05 | 0 | $0 | 86,265 | $152,587 | 0 | $0 |
2024-02 | 0 | $0 | 36,653 | $24,923 | 0 | $0 |
2023-11 | 0 | $0 | 36,702 | $17,982 | 0 | $0 |
2023-09 | 0 | $0 | 8,718 | $6,014 | 0 | $0 |
2023-08 | 0 | $0 | 36,922 | $28,798 | 0 | $0 |
2023-06 | 0 | $0 | 30,000 | $17,100 | 0 | $0 |
2023-05 | 0 | $0 | 37,695 | $27,138 | 0 | $0 |
2023-02 | 0 | $0 | 48,661 | $145,983 | 0 | $0 |
2022-11 | 0 | $0 | 71,259 | $254,393 | 0 | $0 |
2022-09 | 0 | $0 | 55,163 | $133,240 | 0 | $0 |
2022-08 | 0 | $0 | 29,514 | $140,484 | 0 | $0 |
2022-05 | 0 | $0 | 89,219 | $352,412 | 0 | $0 |
2022-02 | 0 | $0 | 41,847 | $458,222 | 0 | $0 |
2021-11 | 0 | $0 | 107,157 | $1,408,773 | 12,500 | $160,000 |
2021-09 | 0 | $0 | 30,209 | $505,519 | 58,279 | $804,250 |
2021-08 | 0 | $0 | 51,485 | $711,225 | 45,000 | $571,500 |
Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
---|---|---|---|---|---|
2025-09-02 | Zalevsky Jonathan (Chief R&D Officer) | Sale | 485 | 30.10 | 14,598 |
2025-09-02 | Robin Howard W (President & CEO) | Sale | 1,500 | 30.16 | 45,240 |
2025-08-19 | Wilson Mark Andrew (Chief Legal Officer) | Sale | 676 | 26.59 | 17,974 |
2025-08-19 | Zalevsky Jonathan (Chief R&D Officer) | Sale | 725 | 26.59 | 19,277 |
2025-08-19 | Robin Howard W (President & CEO) | Sale | 1,573 | 26.59 | 41,826 |
2025-05-19 | Wilson Mark Andrew (Chief Legal Officer) | Sale | 9,996 | .67 | 6,697 |
2025-05-19 | Zalevsky Jonathan (Chief R&D Officer) | Sale | 10,712 | .67 | 7,177 |
2025-05-19 | Robin Howard W (President & CEO) | Sale | 23,208 | .67 | 15,549 |
2025-02-19 | Wilson Mark Andrew (Chief Legal Officer) | Sale | 11,040 | 1.01 | 11,150 |
2025-02-19 | Zalevsky Jonathan (Chief R&D Officer) | Sale | 10,300 | 1.01 | 10,403 |
2025-02-19 | Robin Howard W (President & CEO) | Sale | 23,774 | 1.01 | 24,011 |
2024-12-19 | Zalevsky Jonathan (Chief R&D Officer) | Sale | 51,115 | .94 | 48,048 |
2024-12-18 | Robin Howard W (President & CEO) | Sale | 85,035 | .99 | 84,184 |
2024-12-17 | Robin Howard W (President & CEO) | Sale | 46,995 | 1.01 | 47,464 |
2024-11-19 | Wilson Mark Andrew (Chief Legal Officer) | Sale | 6,407 | 1.01 | 6,471 |
2024-11-19 | Zalevsky Jonathan (Chief R&D Officer) | Sale | 7,785 | 1.01 | 7,862 |
2024-11-19 | Robin Howard W (President & CEO) | Sale | 16,278 | 1.01 | 16,440 |
2024-08-19 | Wilson Mark Andrew (Chief Legal Officer) | Sale | 5,651 | 1.28 | 7,233 |
2024-08-19 | Zalevsky Jonathan (Chief R&D Officer) | Sale | 6,866 | 1.28 | 8,788 |
2024-08-19 | Robin Howard W (President & CEO) | Sale | 14,881 | 1.28 | 19,047 |
2024-06-14 | Chess Robert | Sale | 19,500 | 1.20 | 23,400 |
2024-05-17 | Wilson Mark Andrew (Chief Legal Officer) | Sale | 6,260 | 1.75 | 10,955 |
2024-05-17 | Zalevsky Jonathan (Chief R&D Officer) | Sale | 7,355 | 1.75 | 12,871 |
2024-05-17 | Robin Howard W (President & CEO) | Sale | 16,650 | 1.75 | 29,137 |
2024-05-10 | Kroin David | Sale | 56,000 | 1.78 | 99,624 |
2024-02-20 | Wilson Mark Andrew (Chief Legal Officer) | Sale | 7,606 | .68 | 5,172 |
2024-02-20 | Zalevsky Jonathan (Chief R&D Officer) | Sale | 9,014 | .68 | 6,129 |
2024-02-20 | Robin Howard W (President & CEO) | Sale | 20,033 | .68 | 13,622 |
2023-11-17 | Wilson Mark Andrew (Chief Legal Officer) | Sale | 7,179 | .49 | 3,517 |
2023-11-17 | Zalevsky Jonathan (Chief R&D Officer) | Sale | 9,646 | .49 | 4,726 |
2023-11-17 | Robin Howard W (President & CEO) | Sale | 19,877 | .49 | 9,739 |
2023-09-18 | Curet Myriam (Director) | Sale | 4,359 | .69 | 3,007 |
2023-09-18 | Ajer Jeffrey Robert (Director) | Sale | 4,359 | .69 | 3,007 |
2023-08-16 | Wilson Mark Andrew (Chief Legal Officer) | Sale | 7,221 | .78 | 5,632 |
2023-08-16 | Zalevsky Jonathan (Chief R&D Officer) | Sale | 9,703 | .78 | 7,568 |
2023-08-16 | Robin Howard W (President & CEO) | Sale | 19,998 | .78 | 15,598 |
2023-06-14 | Whitfield Roy A (Director) | Sale | 30,000 | .57 | 17,100 |
2023-05-16 | Wilson Mark Andrew (Chief Legal Officer) | Sale | 7,543 | .72 | 5,430 |
2023-05-16 | Zalevsky Jonathan (Chief R&D Officer) | Sale | 9,791 | .72 | 7,049 |
2023-05-16 | Robin Howard W (President & CEO) | Sale | 20,361 | .72 | 14,659 |
2023-02-16 | Wilson Mark Andrew (Chief Legal Officer) | Sale | 8,275 | 3.00 | 24,825 |
2023-02-16 | Zalevsky Jonathan (Chief R&D Officer) | Sale | 10,484 | 3.00 | 31,452 |
2023-02-16 | Thomsen Jillian B. (Chief Financial Officer) | Sale | 10,267 | 3.00 | 30,801 |
2023-02-16 | Robin Howard W (President & CEO) | Sale | 19,635 | 3.00 | 58,905 |
2022-11-16 | Wilson Mark Andrew (Chief Legal Officer) | Sale | 8,690 | 3.57 | 31,023 |
2022-11-16 | Zalevsky Jonathan (Chief R&D Officer) | Sale | 13,460 | 3.57 | 48,052 |
2022-11-16 | Thomsen Jillian B. (Chief Financial Officer) | Sale | 11,095 | 3.57 | 39,609 |
2022-11-16 | Robin Howard W (President & CEO) | Sale | 38,014 | 3.57 | 135,709 |
2022-09-23 | Curet Myriam (Director) | Sale | 4,198 | 3.16 | 13,265 |
2022-09-23 | Ajer Jeffrey Robert (Director) | Sale | 4,198 | 3.16 | 13,265 |
2022-09-22 | Chess Robert (Director) | Sale | 15,300 | 1.93 | 23,103 |
2022-09-13 | Eastham Karin (Director) | Sale | 21,267 | 3.61 | 76,773 |
2022-08-16 | Wilson Mark Andrew (SVP & General Counsel) | Sale | 3,189 | 4.76 | 15,179 |
2022-08-16 | Zalevsky Jonathan (Chief R&D Officer) | Sale | 10,560 | 4.76 | 50,265 |
2022-08-16 | Thomsen Jillian B. (SVP & Chief Accounting Officer) | Sale | 2,006 | 4.76 | 9,548 |
2022-08-16 | Robin Howard W (President & CEO) | Sale | 13,759 | 4.76 | 65,492 |
2022-05-16 | Wilson Mark Andrew (SVP & General Counsel) | Sale | 3,136 | 3.95 | 12,387 |
2022-05-16 | Zalevsky Jonathan (Chief R&D Officer) | Sale | 21,673 | 3.95 | 85,608 |
2022-05-16 | Northcott John (SVP & Chief Commercial Officer) | Sale | 4,592 | 3.95 | 18,138 |
2022-05-16 | Thomsen Jillian B. (SVP & Chief Accounting Officer) | Sale | 5,841 | 3.95 | 23,071 |
2022-05-16 | Labrucherie Gil M (SVP, COO & CFO) | Sale | 17,448 | 3.95 | 68,919 |
2022-05-16 | Robin Howard W (President & CEO) | Sale | 36,529 | 3.95 | 144,289 |
2022-02-16 | Wilson Mark Andrew (SVP & General Counsel) | Sale | 3,661 | 10.95 | 40,087 |
2022-02-16 | Zalevsky Jonathan (Chief R&D Officer) | Sale | 10,912 | 10.95 | 119,486 |
2022-02-16 | Northcott John (SVP & Chief Commercial Officer) | Sale | 4,852 | 10.95 | 53,129 |
2022-02-16 | Thomsen Jillian B. (SVP & Chief Accounting Officer) | Sale | 2,363 | 10.95 | 25,874 |
2022-02-16 | Labrucherie Gil M (SVP, COO & CFO) | Sale | 7,579 | 10.95 | 82,990 |
2022-02-16 | Robin Howard W (President & CEO) | Sale | 12,480 | 10.95 | 136,656 |
2021-11-18 | Labrucherie Gil M (SVP, COO & CFO) | Sale | 3,000 | 12.69 | 38,070 |
2021-11-16 | Wilson Mark Andrew (SVP & General Counsel) | Sale | 6,564 | 13.16 | 86,382 |
2021-11-16 | Zalevsky Jonathan (Chief R&D Officer) | Sale | 20,869 | 13.16 | 274,636 |
2021-11-16 | Northcott John (SVP & Chief Commercial Officer) | Sale | 6,061 | 13.16 | 79,762 |
2021-11-16 | Thomsen Jillian B. (SVP & Chief Accounting Officer) | Sale | 6,741 | 13.16 | 88,711 |
2021-11-16 | Labrucherie Gil M (SVP, COO & CFO) | Sale | 21,149 | 13.16 | 278,320 |
2021-11-16 | Robin Howard W (President & CEO) | Sale | 42,773 | 13.16 | 562,892 |
2021-11-09 | Greer R Scott (Director) | Option Ex | 12,500 | 12.80 | 160,000 |
2021-09-22 | Curet Myriam (Director) | Sale | 3,665 | 17.78 | 65,163 |
2021-09-22 | Ajer Jeffrey Robert (Director) | Sale | 3,665 | 17.78 | 65,163 |
2021-09-22 | Chess Robert (Director) | Sale | 4,600 | 17.94 | 82,524 |
2021-09-16 | Whitfield Roy A (Director) | Option Ex | 40,000 | 13.80 | 552,000 |
2021-09-09 | Chess Robert (Director) | Sale | 10,279 | 16.02 | 164,669 |
2021-09-09 | Chess Robert (Director) | Option Ex | 10,279 | 13.80 | 141,850 |
2021-09-08 | Chess Robert (Director) | Sale | 8,000 | 16.00 | 128,000 |
2021-09-08 | Chess Robert (Director) | Option Ex | 8,000 | 13.80 | 110,400 |
2021-08-31 | Greer R Scott (Director) | Option Ex | 45,000 | 12.70 | 571,500 |
2021-08-17 | Labrucherie Gil M (SVP, COO & CFO) | Sale | 3,000 | 13.56 | 40,680 |
2021-08-16 | Wilson Mark Andrew (SVP & General Counsel) | Sale | 1,910 | 13.83 | 26,415 |
2021-08-16 | Zalevsky Jonathan (Chief R&D Officer) | Sale | 7,662 | 13.83 | 105,965 |
2021-08-16 | Northcott John (SVP & Chief Commercial Officer) | Sale | 6,192 | 13.83 | 85,635 |
2021-08-16 | Thomsen Jillian B. (SVP & Chief Accounting Officer) | Sale | 13,339 | 13.83 | 184,478 |
2021-08-16 | Labrucherie Gil M (SVP, COO & CFO) | Sale | 7,867 | 13.83 | 108,800 |
2021-08-16 | Robin Howard W (President & CEO) | Sale | 11,515 | 13.83 | 159,252 |
2021-07-22 | Chess Robert (Director) | Sale | 91 | 16.80 | 1,528 |
2021-07-22 | Chess Robert (Director) | Option Ex | 91 | 13.80 | 1,255 |
2021-07-21 | Chess Robert (Director) | Sale | 3,524 | 16.81 | 59,238 |
2021-07-21 | Chess Robert (Director) | Option Ex | 3,524 | 13.80 | 48,631 |
2021-07-20 | Chess Robert (Director) | Sale | 2,106 | 16.80 | 35,380 |
2021-07-20 | Chess Robert (Director) | Option Ex | 2,106 | 13.80 | 29,062 |
2021-05-17 | Wilson Mark Andrew (SVP & General Counsel) | Sale | 1,917 | 18.30 | 35,081 |
2021-05-17 | Zalevsky Jonathan (Chief R&D Officer) | Sale | 31,111 | 18.30 | 569,331 |
2021-05-17 | Northcott John (SVP & Chief Commercial Officer) | Sale | 6,085 | 18.30 | 111,355 |
2021-05-17 | Robin Howard W (President & CEO) | Sale | 11,560 | 18.30 | 211,548 |
2021-05-12 | Chess Robert (Director) | Sale | 8,000 | 19.34 | 154,720 |
2021-05-12 | Chess Robert (Director) | Option Ex | 8,000 | 13.80 | 110,400 |
2021-04-14 | Chess Robert (Director) | Sale | 8,000 | 18.98 | 151,840 |
2021-04-14 | Chess Robert (Director) | Option Ex | 8,000 | 13.80 | 110,400 |
2021-02-16 | Wilson Mark Andrew (SVP & General Counsel) | Sale | 2,173 | 22.37 | 48,610 |
2021-02-16 | Zalevsky Jonathan (Chief R&D Officer) | Sale | 24,141 | 22.37 | 540,034 |
2021-02-16 | Northcott John (SVP & Chief Commercial Officer) | Sale | 15,358 | 22.37 | 343,558 |
2021-02-16 | Thomsen Jillian B. (SVP & Chief Accounting Officer) | Sale | 11,705 | 22.37 | 261,840 |
2021-02-16 | Labrucherie Gil M (SVP, COO & CFO) | Sale | 7,977 | 22.37 | 178,445 |
2021-02-16 | Robin Howard W (President & CEO) | Sale | 11,495 | 22.37 | 257,143 |
2021-02-04 | Labrucherie Gil M (SVP, COO & CFO) | Sale | 50,000 | 19.81 | 990,499 |
2021-02-04 | Labrucherie Gil M (SVP, COO & CFO) | Option Ex | 50,000 | 8.80 | 440,000 |
2021-02-04 | Robin Howard W (President & CEO) | Sale | 150,000 | 20.34 | 3,051,000 |
2021-02-04 | Robin Howard W (President & CEO) | Option Ex | 150,000 | 8.80 | 1,320,000 |
2021-02-03 | Wilson Mark Andrew (SVP & General Counsel) | Sale | 5,344 | 19.45 | 103,940 |
2021-02-03 | Wilson Mark Andrew (SVP & General Counsel) | Option Ex | 5,344 | 8.80 | 47,027 |
2021-02-03 | Labrucherie Gil M (SVP, COO & CFO) | Sale | 50,000 | 19.61 | 980,500 |
2021-02-03 | Labrucherie Gil M (SVP, COO & CFO) | Option Ex | 50,000 | 8.80 | 440,000 |
2021-02-03 | Robin Howard W (President & CEO) | Sale | 150,000 | 19.72 | 2,958,000 |
2021-02-03 | Robin Howard W (President & CEO) | Option Ex | 150,000 | 8.80 | 1,320,000 |
2021-02-02 | Labrucherie Gil M (SVP, COO & CFO) | Sale | 50,000 | 20.86 | 1,043,150 |
2021-02-02 | Labrucherie Gil M (SVP, COO & CFO) | Option Ex | 50,000 | 8.80 | 440,000 |
2021-02-02 | Robin Howard W (President & CEO) | Sale | 150,000 | 20.71 | 3,106,050 |
2021-02-02 | Robin Howard W (President & CEO) | Option Ex | 150,000 | 8.80 | 1,320,000 |
2021-01-28 | Thomsen Jillian B. (SVP & Chief Accounting Officer) | Sale | 75,000 | 18.62 | 1,396,500 |
2021-01-28 | Thomsen Jillian B. (SVP & Chief Accounting Officer) | Option Ex | 75,000 | 8.80 | 660,000 |
2021-01-05 | Greer R Scott (Director) | Option Ex | 40,000 | 13.80 | 552,000 |
2020-12-15 | Myriam Curet (Director) | Sale | 1,560 | 17.82 | 27,799 |
2020-11-23 | Zalevsky Jonathan (Chief R&D Officer) | Sale | 16,380 | 16.40 | 268,632 |
2020-11-16 | Wilson Mark Andrew (SVP & General Counsel) | Sale | 1,539 | 16.93 | 26,055 |
2020-11-16 | Zalevsky Jonathan (Chief R&D Officer) | Sale | 29,618 | 16.93 | 501,432 |
2020-11-16 | Thomsen Jillian B. (SVP & Chief Accounting Officer) | Sale | 11,976 | 16.93 | 202,753 |
2020-11-16 | Robin Howard W (President & CEO) | Sale | 11,975 | 16.93 | 202,736 |
2020-09-28 | Ajer Jeffrey Robert (Director) | Sale | 3,250 | 17.25 | 56,062 |
2020-09-25 | Chess Robert (Director) | Sale | 5,500 | 17.75 | 97,625 |
2020-09-21 | Ajer Jeffrey Robert (Director) | Sale | 2,250 | 19.74 | 44,415 |
2020-09-17 | Labrucherie Gil M (SVP, COO & CFO) | Sale | 2,000 | 19.96 | 39,920 |
2020-09-08 | Chess Robert (Director) | Sale | 8,000 | 18.53 | 148,240 |
2020-09-08 | Chess Robert (Director) | Option Ex | 8,000 | 9.24 | 73,920 |
2020-09-04 | Whitfield Roy A (Director) | Option Ex | 30,000 | 9.24 | 277,200 |
2020-08-18 | Labrucherie Gil M (SVP, COO & CFO) | Sale | 2,000 | 19.68 | 39,360 |
2020-08-17 | Wilson Mark Andrew (SVP & General Counsel) | Sale | 1,529 | 19.67 | 30,075 |
2020-08-17 | Zalevsky Jonathan (Chief R&D Officer) | Sale | 26,200 | 19.67 | 515,354 |
2020-08-17 | Thomsen Jillian B. (SVP & Chief Accounting Officer) | Sale | 1,367 | 19.67 | 26,888 |
2020-08-17 | Labrucherie Gil M (SVP, COO & CFO) | Sale | 6,245 | 19.67 | 122,839 |
2020-08-17 | Robin Howard W (President & CEO) | Sale | 11,885 | 19.67 | 233,777 |
2020-07-09 | Greer R Scott (Director) | Sale | 15,009 | 25.00 | 375,225 |
2020-07-09 | Greer R Scott (Director) | Option Ex | 40,000 | 9.24 | 369,600 |
Insider trading activities including stock purchases, stock sales, and option exercises of NKTR listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Nektar Therapeutics (symbol NKTR, CIK number 906709) see the Securities and Exchange Commission (SEC) website.